Navigation Links
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Date:10/17/2011

SAN DIEGO, Oct. 18, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. Since the subcutaneous administration is an injection under the skin it may allow patients to spend less time in hospital receiving their treatment versus the intravenous method. The ready to use formulation may also significantly reduce pharmacy time as no medicine preparation time is required.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"We are very pleased to see this important program achieve success in a Phase 3 pivotal clinical trial," said Gregory Frost, Ph.D., Halozyme's president and CEO. "The convenience of subcutaneous administration may provide another option for women living with early breast cancer."

No new safety signals were observed and adverse events were overall consistent with Herceptin IV. Data from the trial will be submitted for presentation at an upcoming medical meeting and will support a marketing application to regulatory authorities in the European Union in 2012.

Roche has additional ongoing trials of a subcutaneous formulation of MabThera® (rituximab), using Enhanze™ Technology in pat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... -- Decision Resources Group finds that over half of ... Drug Administration,s (FDA) approval of Vifor Fresenius Medical Care ... by the FDA in November 2013 for the treatment ... dialysis. Other key findings from the report ... : , Bundling: Based ...
(Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... March 16, 2012 Obesity appears to significantly increase the ... rate of mortality even among those prescribed 18 or fewer ... emerged as a marker of increased vulnerability," said Robert ... Epidemiology and Prevention | Nutrition, Physical Activity and Metabolism 2012 ...
... 50th anniversary of Poison Prevention Week , March 18-24, ... pet owners that accidental poisonings are a common problem. ... in the home, and that,s true of pets as well.  ... household items are hazardous to pets.  The AVMA online ...
Cached Medicine Technology:Obesity Raises Death Risk Tied To Sleeping Pills 2Obesity Raises Death Risk Tied To Sleeping Pills 3Obesity Raises Death Risk Tied To Sleeping Pills 4Don't Give Your Pet a Deadly Dose; Medicines Top the List of Household Poisons for Pets 2
(Date:7/13/2014)... Recently, Fadhits.com, the distinguished wedding dress manufacturer ... promotion. According to the company’s senior spokesman, the ... All the company’s current and prospective customers can get ... end of July. , Fadhits.com is a well-known ... customers. The company has its own designers who can ...
(Date:7/13/2014)... 2014 Worldwide ladies are extremely responsive ... has taken a different approach and has created a ... offered in more colour choices that responded directly to ... of women’s special occasion apparels. The company’s pink bridesmaid ... are working hard to create the best products for ...
(Date:7/13/2014)... to get the best treatment and variations in the ... survival for blood cancer patients still varies widely between ... of survival in European adults to date, published in ... is that 5-year survival for most cancers of the ... likely reflecting the approval of new targeted drugs in ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Intraocular Lens ... and Forecast 2013 - 2019 , Intraocular lens (IOL) ... from myopia or cataracts. The lenses are inserted inside ... cataract surgery intraocular lens replaces the focusing power of ... original crystalline lens to deliver the light focusing function ...
(Date:7/13/2014)... Chromatography system is a physical method ... of biological samples such as air and water. ... two phase, namely mobile phase and stationary phase. ... the stationary phase, followed by the differential rate ... separation of mixture. Chromatography system plays an important ...
Breaking Medicine News(10 mins):Health News:Fashionable Pageant Dresses Now On Sale At Fadhits.com 2Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3
... , , , ... With the return of busy school schedules combined ... back-to-basics when it comes to keeping on-the-go families fit and ... trainer, Valerie Waters, have teamed up to create simple solutions ...
... , NEW YORK, Sept. 2 The Prix Galien USA ... D. Sachs, Ph.D., of Columbia University with its 2009 Pro Bono Humanum ... the poorest corners of the globe. , , ... science and economics to global health problems in ways that have changed ...
... , ANN ARBOR, Mich., Sept. ... Commission Strategic Surveillance System (S3) scores through a quality improvement program ... , , Rush-Copley,s efforts were built upon an ... order entry (CPOE) system. , , Following an ...
... , , SAN BERNARDINO, ... stay healthy and well by once again offering seasonal flu ... 17 and run through November 1 at most Stater Bros. ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20030421/STATERLOGO ) , , ...
... , , , , ... Zix Corporation (ZixCorp(R)), (Nasdaq: ZIXI ), the leader in ... This latest agreement is a two-year extension of Humana,s original agreement ... expands the number of ZixCorp licenses bringing the total to 36,000. ...
... Cancer Center has received an $8 million grant from ... Institutes of Health (NCRR/NIH) to expand their laboratory animal ... advanced research into the fundamental biological processes underlying cancer, ... The funds for the grant were made available through ...
Cached Medicine News:Health News:Celebrity Fitness Trainer Valerie Waters Offers On-the-Go Families Back-to-Basics Tips 2Health News:Celebrity Fitness Trainer Valerie Waters Offers On-the-Go Families Back-to-Basics Tips 3Health News:Celebrity Fitness Trainer Valerie Waters Offers On-the-Go Families Back-to-Basics Tips 4Health News:Barry Bloom, Jeffrey Sachs to Be Honored for Introducing Modern Solutions to The World's Oldest Problems: Poverty And Disease 2Health News:Rush-Copley Medical Center Uses Thomson Reuters Order Sets Solution to Improve Joint Commission S3 Scores 2Health News:Rush-Copley Medical Center Uses Thomson Reuters Order Sets Solution to Improve Joint Commission S3 Scores 3Health News:Stater Bros. Helps Customers Fight the Flu 2Health News:Zix Corporation and Humana Renew and Expand Exclusive Agreement 2Health News:Fox Chase Cancer Center receives $8 million NIH grant to expand laboratory animal research facility 2
... Saturated Swabsticks are packaged ... foil-laminated pouches. Each 4 ... with precisely the correct ... package is terminally sterilized, ...
... alcohol and 10% povidone iodine formulated ... a barrier on the skin. The ... the povidone iodine, giving persistent protection ... catheter related infections for up to ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
... Aplicare's saturated swabsticks are packaged in easy ... inch swabstick is saturated with precisely the ... Gel Swabstick is saturated with a multi-purpose ... gel is also approved for venipuncture site ...
Medicine Products: